A Phase I/II Study of the Combination of Temozolomide and Pazopanib in Advanced Pancreatic Neuroendocrine Tumor (PNET)
Phase of Trial: Phase I/II
Latest Information Update: 05 Jun 2018
At a glance
- Drugs Pazopanib (Primary) ; Temozolomide (Primary)
- Indications Neuroendocrine tumours; Pancreatic cancer
- Focus Adverse reactions; Therapeutic Use
- 05 Jun 2018 Results (n=28) presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
- 25 Oct 2017 Planned End Date changed from 1 Aug 2018 to 1 Aug 2020.
- 25 Oct 2017 Planned primary completion date changed from 1 Aug 2017 to 1 Aug 2019.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History